Stock Track | UroGen Pharma Soars 6.09% Intraday After H.C. Wainwright Raises Price Target to $45
Stock Track
May 11
UroGen Pharma Ltd.'s stock surged 6.09% during intraday trading on Monday, following a positive analyst action that boosted investor sentiment.
The rally comes after H.C. Wainwright analyst Raghuram Selvaraju raised the firm's price target on UroGen Pharma to $45 from $40 while maintaining a Buy rating on the shares. This upward revision in the price target represents increased confidence in the company's prospects and valuation.
Analyst price target increases often signal positive expectations for a company's future performance and can trigger buying activity among investors who follow analyst recommendations.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.